Literature DB >> 30900133

Tetrahydrocurcumin-loaded vaginal nanomicrobicide for prophylaxis of HIV/AIDS: in silico study, formulation development, and in vitro evaluation.

Amit Mirani1, Harish Kundaikar1, Shilpa Velhal2, Vainav Patel2, Atmaram Bandivdekar2, Mariam Degani1, Vandana Patravale3.   

Abstract

A vaginal microbicide is a front-line women-dependent approach and an alternative to a condom for prevention of unprotected sexual intercourse-associated HIV. The microbicide research is still in its infancy with several products in the clinical studies being reported to have good efficacy, safe, but with poor adherence. One such molecule reported with an excellent efficacy when tested preclinically is curcumin, a natural polyphenol derived from Curcuma longa. Despite its potential HIV-1 inhibitory activity, it has intense yellow color staining properties, which would result in poor consumer compliance and adherence for vaginal application. To address this issue, tetrahydrocurcumin (THC), a colorless derivative of curcumin, was subjected to in silico screening (molecular docking and dynamics simulation studies) using homology model of gp120-CD4 binding. It was found that THC exhibited equivalent gp120-CD4 binding inhibitory activity as compared with curcumin due to its stable hydrophobic interactions with residues Asp368 and Trp427 deeper in the Phe43 cavity of CD4 receptor. Hence, it can be effectively used as a potential microbicide candidate. THC, a BCS Class II molecule exhibits poor solubility, spreadability, and intracellular uptake when used in the conventional form. Thus, it was decided to develop a lipid-based nanomicrobicide gel for delivery of THC. The developed THC-loaded o/w microemulsion gel was characterized for physicochemical properties (globule size, drug content, drug release, and permeation) and further used for in vitro cell line studies (cell viability, cellular uptake, and anti-HIV activity). The developed formulation was found to be stable with coitus-independent release profile and exhibited a rapid time-independent intracellular uptake. In addition, it exhibited a fourfold increase in efficacy as compared with conventional THC. Thus, the novel THC-loaded o/w microemulsion gel exhibited the potential for prevention of HIV-1 infection associated with unprotected sexual intercourse.

Entities:  

Keywords:  Curcumin; HIV; Molecular docking; Molecular simulation; Prophylaxis; Tetrahydrocurcumin; Vaginal nanomicrobicide

Mesh:

Substances:

Year:  2019        PMID: 30900133     DOI: 10.1007/s13346-019-00633-2

Source DB:  PubMed          Journal:  Drug Deliv Transl Res        ISSN: 2190-393X            Impact factor:   4.617


  36 in total

1.  Controlled release of oral tetrahydrocurcumin from a novel self-emulsifying floating drug delivery system (SEFDDS).

Authors:  Saipin Setthacheewakul; Wichan Kedjinda; Duangkhae Maneenuan; Ruedeekorn Wiwattanapatapee
Journal:  AAPS PharmSciTech       Date:  2010-12-23       Impact factor: 3.246

Review 2.  Nanotechnology-based systems for the treatment and prevention of HIV/AIDS.

Authors:  José das Neves; Mansoor M Amiji; Maria Fernanda Bahia; Bruno Sarmento
Journal:  Adv Drug Deliv Rev       Date:  2009-11-12       Impact factor: 15.470

Review 3.  Self-emulsifying drug delivery systems (SEDDS) for improved oral delivery of lipophilic drugs.

Authors:  R Neslihan Gursoy; Simon Benita
Journal:  Biomed Pharmacother       Date:  2004-04       Impact factor: 6.529

4.  Mono-guanidine heterolipid based SMEDDS: A promising tool for cytosolic delivery of antineoplastics.

Authors:  Harshad Shete; Sandip Sable; Pritish Tidke; Nilakash Selkar; Yogita Pawar; Avik Chakraborty; Abhijit De; Geeta Vanage; Vandana Patravale
Journal:  Biomaterials       Date:  2015-04-24       Impact factor: 12.479

5.  Tetrahydrocurcumin in plasma and urine: quantitation by high performance liquid chromatography.

Authors:  Dennis D Heath; Milagros A Pruitt; Dean E Brenner; Aynun N Begum; Sally A Frautschy; Cheryl L Rock
Journal:  J Chromatogr B Analyt Technol Biomed Life Sci       Date:  2005-09-25       Impact factor: 3.205

6.  Design and evaluation of microemulsions for improved parenteral delivery of propofol.

Authors:  Abhijit A Date; Mangal S Nagarsenker
Journal:  AAPS PharmSciTech       Date:  2008-01-19       Impact factor: 3.246

7.  Antioxidant and radical scavenging properties of curcumin.

Authors:  Tuba Ak; Ilhami Gülçin
Journal:  Chem Biol Interact       Date:  2008-05-07       Impact factor: 5.192

8.  Curcumin and tetrahydrocurcumin both prevent osteoarthritis symptoms and decrease the expressions of pro-inflammatory cytokines in estrogen-deficient rats.

Authors:  Sunmin Park; La Ra Lee; Ji Hyun Seo; Suna Kang
Journal:  Genes Nutr       Date:  2016-03-17       Impact factor: 5.523

9.  Combination antiretroviral drugs in PLGA nanoparticle for HIV-1.

Authors:  Christopher J Destache; Todd Belgum; Keith Christensen; Annemarie Shibata; Akhilesh Sharma; Alekha Dash
Journal:  BMC Infect Dis       Date:  2009-12-09       Impact factor: 3.090

10.  Inhibition of HIV-1 by curcumin A, a novel curcumin analog.

Authors:  Namita Kumari; Amol A Kulkarni; Xionghao Lin; Charlee McLean; Tatiana Ammosova; Andrey Ivanov; Maria Hipolito; Sergei Nekhai; Evaristus Nwulia
Journal:  Drug Des Devel Ther       Date:  2015-09-03       Impact factor: 4.162

View more
  3 in total

Review 1.  Antimicrobial Activity of Curcumin in Nanoformulations: A Comprehensive Review.

Authors:  Jeffersson Krishan Trigo-Gutierrez; Yuliana Vega-Chacón; Amanda Brandão Soares; Ewerton Garcia de Oliveira Mima
Journal:  Int J Mol Sci       Date:  2021-07-01       Impact factor: 5.923

Review 2.  Curcumin as an Antiviral Agent.

Authors:  Morgan R Jennings; Robin J Parks
Journal:  Viruses       Date:  2020-10-31       Impact factor: 5.048

Review 3.  Antimicrobial Potential of Curcumin: Therapeutic Potential and Challenges to Clinical Applications.

Authors:  Yaseen Hussain; Waqas Alam; Hammad Ullah; Marco Dacrema; Maria Daglia; Haroon Khan; Carla Renata Arciola
Journal:  Antibiotics (Basel)       Date:  2022-02-28
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.